Versant Venture Management, LLC
Annual return '25
+28.2%
SPY '25
+17.7%
Alpha
+10.5ptsvs SPY
Invested
$282.8M
Holdings
8
Trades YTD
0
Performance · Fund vs SPY
Cumulative return · quarterly snapshotsCoverage 98%. 4 quarters of 2025 measured against SPY adj-close benchmark.
Top holdings · current snapshot
Source: 13F-HR01
$GLUE
Monte Rosa Therapeutics, Inc.
Held since at least Q1 2024
38.0%
02
$IPSC
Century Therapeutics, Inc.
Held since at least Q1 2024
19.9%
03
$LENZ
Lenz Therapeutics, Inc.
Held since at least Q1 2024
17.6%
04
$JBIO
Jade Biosciences, Inc.
Held since at least Q1 2024
15.5%
05
$CTNM
Contineum Therapeutics, Inc.
Held since at least Q1 2024
5.1%
06
$CRSP
CRISPR Therapeutics AG
Held since at least Q1 2024
2.6%
07
$SKYE
Skye Bioscience, Inc.
Held since at least Q1 2024
0.9%
08
$OVASUSD
Tempest Therapeutics, Inc.
Held since at least Q1 2024
0.3%
Recent trades · Last 90 days
No Form 4 / 13D / 13G trade events on file in the recent window. 13F filers report position snapshots quarterly rather than per-trade events, so this section is most useful for managers who also file Form 4 or 13D/G.
Convergence · Pattern Engine ships in v1.1
30-day windowIn development
Convergence participation lands with the Pattern Engine.
Once the Pattern Engine ships, this section will list every active convergence event this fund is named in — with the other named funds, the Congress members on the same name, and combined position size.
Source data: SEC EDGAR · 13F-HR filings · Performance through 2025-12-31 · Last refreshed 08:22 UTC.